Fighting Large-Scale Untreated Infectious Diseases with Innovative Treatments

Founded in 2020, Meletios is developing innovative antiviral strategies to treat existing and emerging acute viral infections.

Among those, our lead program, presented at the EIC Accelerator, is an oral Host-Directed Agent targeting cell mechanisms hijacked by viruses.

By acting on cell membrane’s fluidity, our antiviral strongly limits cell internalization and intracellular trafficking of viruses.

This approach could be effective against broad virus families, conferring our molecule with an advantageous broad-spectrum effect, a key strategy to boost our capacities to ward off outbreaks.

Moreover, our agent has immunomodulatory effects enabling to efficiently manage viral diseases by preventing excessive immune system reactions. We will perform an accelerated development process as our molecule has already proved it safety in humans.

COVID-19 will be the first demonstrator of our molecule’s efficacy, before targeting diseases induced by other coronaviruses, influenza, flaviviruses.